Bestatin trifluoroacetate (Ubenimex trifluoroacetate) is used as an inhibitor of CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase in cancer research; it enhances ATRA-induced differentiation and inhibits ATRA-driven phosphorylation of p38 MAPK in ATRA-sensitive acute promyelocytic leukemia (APL) NB4 cells; it reduces cell cycle progression by decreasing cell growth rate and frequency of cell division; it inhibits mitosis frequency and inherent multinuclearity in Dictyostelium discoideum without cytotoxicity at concentrations up to 600 μM; it suppresses aminopeptidase activity in cellular lysates; in diabetic mice, it significantly reduces CD13 expression, inhibits MMP-9 gelatinolytic activity, and downregulates the expression of VEGF, heparanase, and HIF-1α in retinas; it enhances humoral immune responses by increasing splenocyte production of hemolytic anti-SRBC antibodies and 2-ME-resistant serum hemagglutinin titers; it modulates immune function in cyclophosphamide-treated mice.